Sign up USA
Proactive Investors - Run By Investors For Investors

Feedback receives long-awaited CE mark for its TexRAD Lung software

TexRAD is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye
lung x-ray
Medical devices are required to have a CE mark before they can legally be sold in the European Union

Specialist medical imaging group Feedback plc (LON:FDBK) has finally received a CE mark for its TexRAD Lung technology.

The company had previously expected the CE mark by the end of May but several enhancements that have improved the performance of TexRAD Lung led to a delay.

READ: Feedback to squeeze in more enhancements to TexRAD Lung ahead of CE mark ruling

Distilled to its basics, TexRAD is a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

By analysing “texture features” in CT scans, TexRAD's quantitative imaging capabilities provide clinicians with additional information to make better decisions in order to improve patient outcomes.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

Next step, liver cancer and COPD

"TexRAD Lung is our first TexRAD product with a CE mark which represents a significant accomplishment,” said chairman Alastair Riddell.

“This development will expedite TexRAD's clinical use in the treatment of lung cancer across the EU, expand its market presence and support the Company's ongoing commercial discussions for the technology.

"We expect that the rigorous regulatory review required for the CE mark will pave the way for TexRAD's clinical use worldwide and we are now investigating the clinical application of TexRAD in liver cancer and chronic obstructive pulmonary disease (COPD).

He added: “By arming clinicians with disease-specific tools, we believe this technology has the potential to transform radiological decision making.”

View full FDBK profile View Profile

Feedback plc Timeline

Related Articles

Medical Scan
August 03 2018
TexRAD is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye
Light fittings
August 23 2018
The group's traditional LED business is operating in a fiercely competitive environment. The group is pinning its hopes on becoming a software and services business
Hydrogen refuelling
October 02 2018
As the move towards alternative fuels for vehicles gathers pace, news last month of the opening of the first 'under the canopy' hydrogen refuelling station at Beaconsfield Services on the M40 deserved a bit of a fanfare

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use